Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis.

Néboa ZozayaFernando AbdallaSantiago Alfonso ZamoraJesús Balea FilgueirasY José Manuel CarrascosaOlga Delgado SánchezFrancisco Dolz SinisterraAntonio J Garcia-RuizPedro Herranz PintoAntonio ManfrediJosé Martínez OlmosPaloma Morales de Los Ríos LunaLluis L PuigSandra RosÁlvaro HIdalgo-Vega

Published in: Expert review of pharmacoeconomics & outcomes research (2022)

Under a methodology with increasing use in the health field, bimekizumab was evaluated as a drug with a high added value for the treatment of moderate-to-severe psoriasis when compared to six different alternatives.

Keyphrases

healthcare
public health
early onset
high intensity
drug induced
decision making
social media
quality improvement
replacement therapy
electronic health record